Perspective Therapeutics is a precision oncology company focused on targeted alpha particle therapies (TAT) and innovative brachytherapy solutions intended to treat cancer from the inside out. The company's development pipeline is focused on Lead-212 alpha particle-based radiopharmaceuticals for the diagnosis and treatment of NETs, melanoma and other solid tumors. The commercial pipeline is focused on Cesium-131 seed brachytherapy for the treatment of prostate, brain and head and neck cancers. Perspective’s clinical stage platform leverages the perfect theranostic pairing of Pb-203 for imaging and Pb-212 for therapy with minimal risk of toxicity. Our portfolio also includes an emerging pipeline of novel targeted peptides against a broad range of solid tumors with high unmet need. We also possess expertise in the development of therapeutic combinations of TAT with immune checkpoint inhibitors and TKI's.